Man Group
TPTX

Man Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Man Group’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Hold
0
– – – 752
2021
Q2 		– Sell
-21,860
Closed -$2.07M – 2151
2021
Q1 		$2.07M Sell
21,860
-21,864
-50% -$2.6M 0.01% 1093
2020
Q4 		$5.33M Sell
43,724
-25,864
-37% -$2.83M 0.02% 772
2020
Q3 		$6.08M Sell
69,588
-24,724
-26% -$1.72M 0.02% 710
2020
Q2 		$6.09M Buy
94,312
+77,183
+451% +$4.45M 0.03% 576
2020
Q1 		$765K Buy
+17,129
New +$910K 0.01% 1177

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Man Group's TPTX Position: Q2 2022 in Review

Man Group held its Turning Point Therapeutics, Inc. Common Stock (TPTX) position steady in Q2 2022 at 0 shares worth $5.51M. The position accounts for 0.02% of the portfolio, ranked #752.

Man Group first reported a position in TPTX in Q1 2020 and has held it in 5 quarters since. The position peaked at $6.09M in Q2 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

  • Man Group held 0 shares of Turning Point Therapeutics, Inc. Common Stock worth $5.51M as of Q2 2022.
  • Man Group left its Turning Point Therapeutics, Inc. Common Stock share count unchanged in Q2 2022.
  • Turning Point Therapeutics, Inc. Common Stock made up 0.02% of Man Group's portfolio in Q2 2022, its #752 holding.
  • Man Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and has held it in 5 quarters since.
  • Man Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $6.09M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.